CeRAI at IIT-Madras partners with Roche for AI research in diagnostics, focusing on responsible and ethical AI solutions.

Quest Diagnostics Inc. hit a new 52-week high, surpassing its previous peak of $168.17, which the company achieved on February 11th.

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

Detailed price information for Butterfly Network Inc (BFLY-N) from The Globe and Mail including charting and trades.

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Cervical cancer remains a major health challenge for Indian women, despite being preventable through early screening and ...

Following the earnings announcement, Quest Diagnostics (NYSE:DGX)' stock price rose by 0.48% in pre-market trading. The stock's recent movement places it near its 52-week high of $167.08, indicating ...

Diagnostics may not be as profitable as Pharmaceuticals ... Concluding Thoughts: Is Roche Stock A “Best Buy” Within Big Pharma In 2025? As a Roche shareholder myself, am I looking forward ...

The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...